ABHD5 and metabolic dysfunction-associated steatohepatitis: Our findings provide the first proof-of-principle evidence in support of our hypothesis that targeting lipid droplet formation, the PAT family lipid droplet coat proteins in particular, is sufficient to prevent fatty liver and nonalcoholic steatohepatitis (NASH) associated with hepatocyte CGI-58 deficiency and overnutrition.